Biomarker analysis
At baseline, from the seven safety-evaluable patients with available data at baseline and cycle 2 day 28 (C2D28), four patients had Evolution of all patients with Amcenestrant demonstrated robust trends of antitumor activity as shown by overall reductions (expressed as median relative change from screening) in ER protein expression (− 46.4%; range, − 100% to 1733%; There was an overall increase in Bcl-2 expression (H-score, IHC; median relative change from screening: 56.2%; range, − 55.6% to 275%; 